University of Oxford – Confidence in Concept 2019
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
People |
ORCID iD |
| Matthew Wood (Principal Investigator) |
Publications
Aitken C
(2023)
Mechanisms of endothelial flow sensing.
in Nature cardiovascular research
Ali K
(2023)
xTMS: A Pulse Generator for Exploring Transcranial Magnetic Stimulation Therapies.
in Conference proceedings. IEEE Applied Power Electronics Conference and Exposition
Bellingrath J
(2023)
Programmable RNA editing with endogenous ADAR enzymes - a feasible option for the treatment of inherited retinal disease?
in Frontiers in Molecular Neuroscience
Bruce R
(2025)
Incongruent virtual reality cycling exercise demonstrates a role of perceived effort in cardiovascular control
in The Journal of Physiology
Chen J
(2022)
MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
in Clinical Lymphoma Myeloma and Leukemia
Chen James
(2022)
Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Chwalenia K
(2022)
Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties
in Molecular Therapy - Nucleic Acids
Cui J
(2024)
Extended-period AOSLO imaging in the living human retina without pupil dilation: a feasibility study.
in Biomedical optics express
| Description | Advanced retinal imaging: Enabling access to neural and vascular circuits in the living human eye (Philanthropic funding (via MSD)) |
| Amount | £130,000 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 06/2024 |
| End | 12/2026 |
| Description | Advancing Oligonucleotide Therapeutics |
| Amount | £951,725 (GBP) |
| Funding ID | BB/W003902/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | BMS Fellowship |
| Amount | £660,607 (GBP) |
| Organisation | Bristol-Myers Squibb |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 08/2022 |
| Description | Decision-support for individualised risk assessment of fetal health during labour: preventing fetal brain damage and death by utilising large, routinely collected datasets of cardiotocography and clinical risk factors |
| Amount | £1,118,105 (GBP) |
| Funding ID | NIHR202117 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 04/2024 |
| Description | Design of HLAE- targeted adopWve cell therapies for acute myeloid leukaemia (AML) |
| Amount | £124,164 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2024 |
| End | 09/2028 |
| Description | Developing Raman micro-spectroscopy to determine the OXPHOS /glycolysis status of patient tumours |
| Amount | £10,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Development of a CRISPR treatment for USH2A-associated retinitis pigmentosa |
| Amount | £60,000 (GBP) |
| Organisation | The Royal College of Surgeons of Edinburgh |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Direct Costs for Devices |
| Amount | £25,000 (GBP) |
| Organisation | The Magstim Company Limited |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Doctoral studentship |
| Amount | £30,000 (GBP) |
| Organisation | University of Oxford |
| Department | Magdalen College Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | EPSRC Healthcare Technology |
| Amount | £600,699 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Early Career Award - Translating the potential of human regulatory B cells |
| Amount | £1,060,778 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 10/2028 |
| Description | Graft versus Leukaemia (GvL): Identification & characterisation of GVL antigens and cognate T cell responses in Acute Myeloid Leukaemia |
| Amount | £302,075 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | HLA-E targeted T cell receptor therapy for Acute Myeloid Leukaemia (MLSTF) |
| Amount | £25,370 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 06/2022 |
| Description | Harnessing the Graft-versus-Leukaemia Effect in Acute Myeloid Leukaemia |
| Amount | £858,703 (GBP) |
| Organisation | Bristol-Myers Squibb |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | MRC Collaboration Grant |
| Amount | £200,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC Unit programme grant |
| Amount | £2,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MSD Bridging salary scheme |
| Amount | £33,403 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Matched funding |
| Amount | £37,500 (GBP) |
| Organisation | Novo Nordisk |
| Sector | Private |
| Country | Denmark |
| Start | |
| Description | Medical and Life Sciences Translational Fund (MLSTF) 2024: The use of stimulation induced evoked potentials for closed-loop DBS programming and titration |
| Amount | £80,000 (GBP) |
| Funding ID | Project Reference Number: 0014647 |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2024 |
| End | 05/2025 |
| Description | PLXND1 in cardiometabolic diseases |
| Amount | £359,297 (GBP) |
| Organisation | Novo Nordisk |
| Sector | Private |
| Country | Denmark |
| Start | |
| Description | Pre-clinical validation of a Braided Electrospun Cord designed for ACL reconstruction (MRC DPFS) |
| Amount | £1,500,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Proof-of-Concept Lentiviral gene therapy to treat babies born with lung surfactant deficiency caused by mutations in ABCA3 gene |
| Amount | £272,474 (GBP) |
| Organisation | Action Medical Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 06/2025 |
| Description | RNA editing-mediated uORF disruption - molecular therapies for haploinsufficiency disorder |
| Amount | £74,629 (GBP) |
| Organisation | Medical and Life Sciences Translational Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Smart electroceuticals for neurological disorders (SEND) |
| Amount | £192,417 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2022 |
| End | 05/2025 |
| Description | Studying the coevolving cancer and immune landscapes - unravelling targetable pathways of immune adaptation |
| Amount | £1,489,252 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2024 |
| End | 05/2030 |
| Description | Therapeutic and diagnostic opportunities for discordant sensory stimulation with virtual reality cycling |
| Amount | £399,934 (GBP) |
| Organisation | JABBS Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2024 |
| End | 01/2027 |
| Description | Towards a therapy for KCNQ2 developmental and epileptic encephalopathy (John Fell Fund) |
| Amount | £74,172 (GBP) |
| Organisation | Oxford University Press |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 09/2024 |
| Description | TransNAT: Transforming delivery, safety and efficacy of nucleic acid therapeutics: from intracellular uptake to targeting brain and muscle. |
| Amount | £8,000,000 (GBP) |
| Funding ID | MR-X008029-1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2022 |
| End | 10/2025 |
| Title | xTMS: Flexible Transcranial Magnetic Stimulation System |
| Description | The xTMS system is a programmble transcranial magnetic stimulator device. The xTMS system enables more control on the electric field pulse shape than conventional TMS device. The pTMS2 system enables PWM electric field pulse with control over the pulse shape, duration, directionality, pulse type such as mono-phasic, bi-phasic and polyphasic. It can be used in single pulse mode or repetitive TMS mode. The xTMS system requires a stimulation coil to deliver the magnetic stimulation. Brief stimuli of an electromagnetic field are applied to the neural tissues with current-carrying treatment coils. The fast-changing field induces electrical currents within the neurons and modulates cell activity. Using the xTMS device, it is possible to change the stimulus waveform and polarity of each pulse in the pulse train. It is intended for use by, or under the supervision of, a medical practitioner or investigator who has knowledge about the principles of TMS, physiology and potential side effects of TMS. It's the user's responsibility to design and validate safeness of their stimulation protocols. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2021 |
| Provided To Others? | Yes |
| Impact | We have completed the first clinical study using the xTMS approach, and have now initiated a second study at Oxford. For this year, we are expanding to collaborations at King's College, London and Cambridge University. The studies are in publication review. Note that this project includes a collaboration with Magstim Ltd in Whitland Wales, who is supplying TMS coils for researchers to use. |
| Description | An academic (non-commercial) licensing agreement with King's College London who are performing academic research with our technology. |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | NK |
| Collaborator Contribution | King's College London are performing academic research with our technology. |
| Impact | NK |
| Start Year | 2023 |
| Description | Collaborative agreement with NovoNordisk for 1 year. |
| Organisation | Novo Nordisk |
| Country | Denmark |
| Sector | Private |
| PI Contribution | Research collaborative agreement with NovoNordisk. |
| Collaborator Contribution | The objectives of the project were met, which raised more interesting questions that were later followed up as a research collaborative agreement with NovoNordisk. |
| Impact | NK |
| Start Year | 2021 |
| Description | Licensing Agreement: rSIV.F/HN technology licensed for cystic fibrosis to Boehringer Ingelheim and for a range of other disorders to AlveoGene |
| Organisation | Boehringer Ingelheim |
| Country | Germany |
| Sector | Private |
| PI Contribution | Partnership with Boehringer Ingelheim to develop rSIV.F/HN technology for Cystic Fibrosis |
| Collaborator Contribution | The applicants have partnered with Boehringer Ingelheim to develop rSIV.F/HN technology for Cystic Fibrosis |
| Impact | NK |
| Start Year | 2022 |
| Description | Part of the follow-up MRC Grant TransNAT. |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Part of the follow-up MRC Grant TransNAT. |
| Collaborator Contribution | Part of the follow-up MRC Grant TransNAT. |
| Impact | NK |
| Start Year | 2022 |
| Description | Part of the follow-up MRC Grant TransNAT. |
| Organisation | Silence Therapeutics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Part of the follow-up MRC Grant TransNAT. |
| Collaborator Contribution | Part of the follow-up MRC Grant TransNAT. |
| Impact | NK |
| Start Year | 2022 |
| Description | Partnership with with Boehringer Ingelheim to develop rSIV.F/HN technology for Cystic Fibrosis |
| Organisation | Boehringer Ingelheim |
| Country | Germany |
| Sector | Private |
| PI Contribution | Develop rSIV.F/HN technology for Cystic Fibrosis |
| Collaborator Contribution | Develop rSIV.F/HN technology for Cystic Fibrosis |
| Impact | NK |
| Start Year | 2022 |
| Description | xTMS collaboration |
| Organisation | The Magstim Company Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The economic cost of neurological disorders exceeds £100B/yr in the UK alone, and new technologies that might provide therapeutic solutions are increasingly attractive. This project will deliver a versatile scientific instrument for non-invasive actuation of the nervous system using Transcranial Magnetic Stimulation (TMS). The new system, MAGNETO, closes key performance gaps in stimulation capability that enables new therapeutic potential for neurological disorders. We have already secured lead clinical users at Oxford, King's College, UCL and Cambridge to apply the tool to explore novel therapies for high-need areas in stroke, epilepsy, motor systems and neuropsychiatry (depression, anxiety), respectively. Their insights will guide the design process and maximise translation probability. With the guidance of these lead-users, MAGNETO will enable: 1) the ability to prescribe novel patterns of stimulation enabled with our unique technology, 2) the modelling of the magnetic coupling to the neural interface for exploring optimal pulse parameters, and 3) real-time control capability for automated exploration of pulse shape and patterns. The key deliverable will be a fully-integrated prototype medical device suitable for first-in-human studies. The expectation is that these studies focus on the clinical translation of therapies for major neurological disorders. |
| Collaborator Contribution | Magstim has provided direct funds for the transistors and power electronic assemblies for the prototypes to support Oxford, Cambridge and King's. For in-kind, they have provided TMS coils and electronics, design guidance, regulatory guidance, and human factors feedback throughout the project. |
| Impact | Publications are noted in the publications tab. Our outcome for the xTMS tool is noted in the research platforms/instrumentation support tab. |
| Start Year | 2020 |
| Title | GENERATION OF CONTROLLABLE MAGNETIC STIMULI |
| Description | A stimulation circuit generates magnetic stimulation for application to a body organ using a coil arrangement. A DC supply is provided and supplied to a DC/AC inverter that comprises a bridge inverter stage comprising plural switch modules connected in a bridge arrangement between input terminals and output terminals for supplying the stimulation signal. A driver circuit supplies pulse width modulation control signals to the switch modules that are selected to control the DC/AC inverter to generate the stimulation signal with pulse width modulation of voltage, thereby providing for a high degree of control of the form of the stimulation. |
| IP Reference | WO2021176219 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2021 |
| Licensed | Yes |
| Impact | OUI in collaboration with our team has reached a licensing agreement for the IP. The agreement includes the two patents and the prototype design. Magstim has agreed to an aggressive development plan which includes a Research Use Only device to be launched to the global market within 2024/2025 and a regulatory approved clinical product launched by 2027. The license is worldwide and exclusive for the field of TMS and includes upfront and milestone payments and royalty payments for all resulting product lines. The academic team continues collaboration with Magstim to facilitate and accelerate product development and share clinical outcomes. A prominent member of the team has joined Magstim as an employee, which will help with efficient knowledge transfer. |
| Title | METHOD AND COMPOSITION |
| Description | The invention relates to a method of selecting an immunotherapeutic agent for treating a disease in an individual, and to treatment of the disease by administering the immunotherapeutic agent or the cognate peptide antigen for the immunotherapeutic agent. The invention also relates to an antigen binding molecule that binds to the peptide antigen. |
| IP Reference | WO2022223970 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | Yes |
| Impact | n a pilot experiment, we stimulated PBMCs from one patient with overlapping putative GvL peptides identified by IFNy ELISpot mapping (see Figure 3), or control peptides, FACS-sorted responding T cells (identified by IFNy-secretion using a catch reagent) and successfully subjected them to parallel single cell TCR/transcriptome sequencing (10X genomics platform) (Keskin, D.B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase lb glioblastoma trial. Nature, 2019. 565(7738): p. 234-239). Analysis of the data has enabled identification of TCRs highly enriched in the peptide-responsive population, and simultaneous interrogation of their gene expression profile. Bulk TCR sequencing was also performed on an unstimulated ex vivo sample from the same patient, to enable determination of the frequency of each peptide-responsive TCR within the in vivo T cell repertoire. This established a workflow in our laboratory that can readily be applied to the larger sample set from the AMADEUS trial. |
| Title | Optimisation of control of reactive circuit for generating electromagnetic pulses |
| Description | Covers a method of optimising digital pulsing sequencing to a series of power electronic drives to produce the desired magnetic stimulation pulses at the TMS coils. |
| IP Reference | |
| Protection | Patent / Patent application |
| Year Protection Granted | |
| Licensed | No |
| Impact | OUI in collaboration with our team has reached a licensing agreement for the IP. The agreement includes the two patents and the prototype design. Magstim has agreed to an aggressive development plan which includes a Research Use Only device to be launched to the global market within 2024/2025 and a regulatory approved clinical product launched by 2027. The license is worldwide and exclusive for the field of TMS and includes upfront and milestone payments and royalty payments for all resulting product lines. The academic team continues collaboration with Magstim to facilitate and accelerate product development and share clinical outcomes. A prominent member of the team has joined Magstim as an employee, which will help with efficient knowledge transfer. |
| Title | Systems and methods for measuring a response of a subject to an event. |
| Description | Systems and methods for measuring a response of a subject to an event. |
| IP Reference | UK IPO : 2116218.5 |
| Protection | Patent / Patent application |
| Year Protection Granted | |
| Licensed | Commercial In Confidence |
| Impact | n/k |
| Title | Un procedimiento para extraer y para botar embarcaciones. |
| Description | Development of a monolithic filter system for the enrichment of bacteria from liquid biopsies in a manner compatible with microscopy |
| IP Reference | ES20891 |
| Protection | Patent / Patent application |
| Year Protection Granted | 1897 |
| Licensed | No |
| Impact | NK |
| Company Name | Orfonyx |
| Description | Orfonyx develops a range of drugs that target and activate specific genes. |
| Year Established | 2022 |
| Impact | Is currently operating at the Oxford BioEscalator (£5 million seed raise) as of late November 2022 |
| Website | https://orfonyx.com/ |
| Description | American Association of Cancer Research Myeloid Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Title: "Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia (AML)" Co-authors: Alberto Risueño, PhD, Wendy L. See, PhD, Courtney D. DiNardo, MD, MSCE, Hartmut Döhner, MD, Eytan Stein, MD5, Amir T. Fathi, MD6, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath, Lynn Quek, MD PhD, Thomas Prebet, MD, PhD, Anita K. Gandhi, PhD9 and Maroof Hasan, MD |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://ash.confex.com/ash/2022/webprogram/Session22525.html |
| Description | Belgian Academy of Sciences |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Paresh VYAS (Professor of Haematology at the University of Oxford, Oxford, UK) : Paresh Vyas : Clonal Cell Heterogeneity in Tissues With Aging Alters Function: Using Whole Genome Sequencing and Single Cell Sequencing To Study These Processes In Blood Cells As An Exemplar Ruud Delwel (Professor "Molecular Leukemogenesis", Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands): How good genes can become Evil in leukemia Steven O. Smith (Professor - Director of Structural Biology, Department of Biochemistry and Cell Biology Stony Brook, NY USA) : Lessons from brain-derived amyloid fibril structures from Alzheimer's Disease patients https://www.youtube.com/watch?v=GjyrzYunfPU See also: https://www.facebook.com/probramedecine/ |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.youtube.com/watch?v=GjyrzYunfPU |
| Description | Characterisation of Border Areas in Bladder Tumour Grading with Bayesian Graph Neural Networks |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | We have a paper accepted in the 21st IEEE International Symposium on Biomedical Imaging, which will be held in Athens, Greece, May 27-30, 2024, entitled: "Characterisation of Border Areas in Bladder Tumour Grading with Bayesian Graph Neural Networks" Authors: Shangqi Gao, Lisa Browning, Nasullah Khalid Alham, Andrew Protheroe , Keir Edwards, Josh Hamblin, Jens Rittscher and Clare Verrill. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Conference / Exposition: American Association of Cancer Research Myeloid Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Title: "Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia (AML)" Co-authors: Alberto Risueño, PhD, Wendy L. See, PhD, Courtney D. DiNardo, MD, MSCE, Hartmut Döhner, MD, Eytan Stein, MD5, Amir T. Fathi, MD6, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath, Lynn Quek, MD PhD, Thomas Prebet, MD, PhD, Anita K. Gandhi, PhD9 and Maroof Hasan, MD |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://ash.confex.com/ash/2022/webprogram/Session22525.html |
| Description | Conference / Exposition: University of Texas South Western |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | PLENARY SESSION 8: CELL AND IMMUNE TARGETING IN MYELOID MALIGNANCIES SESSION CHAIR: PARESH VYAS, UNIVERSITY OF OXFORD, OXFORD, UNITED KINGDOM 12:00 P.M.-1:45 P.M. Talk title: "Graft versus Leukemia (GvL): Identification and characterization of alloreactive antigens and cognate T cell responses in acute myeloid leukemia" |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.aacr.org/meeting/acute-myeloid-leukemia-and-myelodysplastic-syndrome/program/ |
| Description | EHA (European Haematology Association) Annual Meeting. |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS Dr. Naval G Daver Author(s): Naval G Daver, Paresh Vyas, Suman Kambhampati, Monzr M Al Malki, Richard Larson, Adam Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany Tanaka, Terrence Bradley, Deepa Jeyakumar, Eunice Wang, Guan Xing, Mark Chao, Giri Ramsingh, Camille Renard, Indu Lal, Joshua Zeidner, David Sallman (Abstract release date: 05/26/22) EHA Library. G Daver N. 06/10/2022; 356996; S132 |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://library.ehaweb.org/eha/2022/eha2022-congress/356996/naval.g.daver.tolerability.and.efficacy.... |
| Description | ESH (European Society of Haematology) Treatment of Leukaemias (Virtual) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | (Latest session from 2022 not recorded. Earlier talk from 2019 recorded at URL provided below): The AML Global Portal were delighted to speak to Paresh Vyas, University of Oxford, Oxford, UK, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Paresh Vyas: When do you use single-cell MRD assessment in AML? Paresh Vyas discusses the role of measurable residual disease (MRD) monitoring in informing clinical practice and reviews different approaches such as next-generation sequencing (NGS), flow cytometry and single-cell measurement of disease. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://aml-hub.com/medical-information/esh-2019-or-when-do-you-use-single-cell-mrd-assessment-in-am... |
| Description | Experts in Residence meeting with Aptus Clnical |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | The project team engaged with Aptus Clinical via the experts in residence scheme. Our research team received very valuable advice on investor deck preparation and how to prepare for industry engagement activities. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Industry engagement activities with Magstim |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The research team is engaged iwith Magstim, a potencial disctributor for the technology developed under the project. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Industry engagement activities with Philips and Huntleigh Healthcare |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The research team has enaged with two major market leaders, Philips and Huntliegh Healthcare, with regards to market access and commercialisation of the Fit for Labor test. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Myeloid Workshop (Cincinnati, USA) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Since 1995, the Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia has offered a highly successful presentation series from approximately 40-50 renowned national and international researchers and clinicians. The goal of these biennial workshops is to bring together investigators with expertise in complementary aspects of stem cell biology and myelopoiesis - from normal myelopoiesis to myeloid leukemias and myelodysplastic/myeloproliferative syndromes. Basic researchers and clinician investigators from both sides of the Atlantic, Australia and Japan come together biennially to discuss their latest findings in a close and informal setting. The workshop brings together scientists with expertise in normal and abnormal hematopoiesis and clinicians who treat leukemia/MDS/MPD patients and also have active research programs in these diseases. Participants achieve a better understanding of critical steps/factors that regulate hematopoiesis, their impact in leukemogenesis, and potential relevance in clinical settings. Although there are other workshops and meetings dedicated to understanding the regulation of hematopoiesis or clinical advances in leukemia, this workshop uniquely brings together both clinicians and scientists in a relaxed forum. Speakers: (See URL) |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://myeloidmeeting.org |
| Description | New Scientist Live 2024 in London |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Unit researchers recently brought cutting-edge neuroscience to the public through interactive exhibits and live demonstrations at this year's New Scientist Live event, held in London from 12th to 14th October. New Scientist Live is a huge festival of ideas and discoveries, showcasing the latest in science and technology, with an attendance of over 25,000 people. Visitors to the MRC BNDU stand were invited to immerse themselves in the latest advances in neuroscience, exploring how researchers can decode brain signals to understand movement, memory, and early indicators of neurological disorders. The Unit stand was a hub of hands-on activities, offering visitors a chance to see a brain-machine interface (BMI) in action and to witness how these innovative technologies may transform communication and interaction. Visitors were talked through each activity by some of the Unit's early-career researchers. Postdoctoral researcher Shenghong He from my lab demonstrated the potential of BMI by spelling words on a screen using signals from his brain, recorded by an electroencephalogram (EEG) cap. This demonstration captivated audiences and led to discussions about how we can utilise brain waves in the future. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.mrcbndu.ox.ac.uk/news/unit-brings-neuroscience-research-public-new-scientist-live-2024 |
| Description | Symphony of the Brain |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | We are delighted to announce that the Unit's public outreach film 'The Symphony of the Brain', produced in collaboration with Oxford Sparks, has received international recognition at the #LabMeCrazy! International Science Film Festival. The Festival is an initiative of the Science Museum of the University of Navarra, Spain, which aims to bring science closer to young people by featuring refreshing displays of science and the communication of science. Beating out stiff competition from another seven finalists, the Unit's film won the first prize in the category 'work produced by universities and research centres'. The jury was particularly impressed by how the analogy of music and a choir made a complex topic such as brain research accessible to a broad audience, as well as the film's overall production. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.mrcbndu.ox.ac.uk/news/international-recognition-symphony-brain |
| Description | Unit Open Day 2024 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | On 14th March, the MRC Brain Network Dynamics Unit once again welcomed stakeholders onsite for its annual Open Day. In the morning, the Unit opened its doors to pupils and teachers from local state-funded schools as they visited to learn more about STEM (Science, Technology, Engineering and Mathematics) and medical research. During their visits, pupils talked informally to Unit staff and students about key concepts and challenges in brain research, as well as careers in STEM. Special emphasis was also placed on giving pupils the opportunity to see real working instruments and laboratories. My lab demosntrated EEG measurement, brain-machine interfaces to the visiting pupils. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.mrcbndu.ox.ac.uk/news/unit-open-day-2024 |
| Description | University of Texas South Western |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | PLENARY SESSION 8: CELL AND IMMUNE TARGETING IN MYELOID MALIGNANCIES SESSION CHAIR: PARESH VYAS, UNIVERSITY OF OXFORD, OXFORD, UNITED KINGDOM 12:00 P.M.-1:45 P.M. TITLE: "Graft versus Leukemia (GvL): Identification and characterization of alloreactive antigens and cognate T cell responses in acute myeloid leukemia" |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.aacr.org/meeting/acute-myeloid-leukemia-and-myelodysplastic-syndrome/program/ |
| Description | iWAL (International Workshop on Acute Leukemia) Workshop (Nice, France): iWAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | iwAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML Tuesday Dec 06, 2022 The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year's meeting. In this podcast, Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, and Carsten Müller-Tidow, MD, University Hospital Heidelberg, Heidelberg, Germany, discuss mechanisms of resistance to targeted therapies in AML, and the role of epigenetics. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://vjhemonc.podbean.com/e/iwal-2022-session-v-mechanisms-of-resistance-to-targeted-therapies-in... |